LP
PTCT icon

Longaeva Partners’s PTC Therapeutics PTCT Stock Holding History

Longaeva Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.12M Buy
+111,803
New +$8.07M 0.2% 113

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Longaeva Partners's PTCT Position: Q2 2026 in Review

Longaeva Partners opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 111,803 shares worth $9.12M. The stake represents 0.2% of the portfolio and ranks #113 among its holdings.

382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Longaeva Partners held 111,803 shares of PTC Therapeutics worth $9.12M as of Q2 2026.
  • PTC Therapeutics was a new Longaeva Partners position in Q2 2026.
  • PTC Therapeutics made up 0.2% of Longaeva Partners's portfolio in Q2 2026, its #113 holding.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.